BACKGROUND: Elevated endogenous plasma erythropoietin (EPO) levels have been associated with protection from acute neurologic deficits in Kenyan children with cerebral malaria (CM). Based on these findings and animal studies, clinical trials of recombinant human EPO (rHuEPO) have been started in children with CM. Recent clinical trials in adults with acute ischemic stroke have demonstrated increased mortality with rHuEPO treatment. We conducted a study in children with CM to assess the relationship of endogenous plasma and cerebrospinal fluid (CSF) EPO levels with mortality and acute and long-term neurologic outcomes. METHODS: A total of 210 children between 18 months and 12 years of age with a diagnosis of CM, were enrolled at Mulago Hospital, Kampala, Uganda. Plasma (n = 204) and CSF (n = 147) EPO levels at admission were measured by radioimmunoassay and compared with mortality and neurologic outcomes. RESULTS: After adjustment for age and hemoglobin level, a 1-natural-log increase in plasma EPO level was associated with a 1.74-fold increase in mortality (95% confidence interval, 1.09-2.77, P = .02). Plasma and CSF EPO levels also correlated positively with coma duration (P = .05 and P = .02, respectively). Plasma and CSF EPO levels did not differ in children with vs those without acute or long-term neurologic deficits. Plasma EPO levels correlated positively with markers of endothelial and platelet activation and histidine-rich protein-2 levels, but remained associated with mortality after adjustment for these factors. CONCLUSIONS: High endogenous plasma EPO levels are associated with prolonged coma duration and increased mortality in children >18 months of age with CM.
BACKGROUND: Elevated endogenous plasma erythropoietin (EPO) levels have been associated with protection from acute neurologic deficits in Kenyan children with cerebral malaria (CM). Based on these findings and animal studies, clinical trials of recombinant humanEPO (rHuEPO) have been started in children with CM. Recent clinical trials in adults with acute ischemic stroke have demonstrated increased mortality with rHuEPO treatment. We conducted a study in children with CM to assess the relationship of endogenous plasma and cerebrospinal fluid (CSF) EPO levels with mortality and acute and long-term neurologic outcomes. METHODS: A total of 210 children between 18 months and 12 years of age with a diagnosis of CM, were enrolled at Mulago Hospital, Kampala, Uganda. Plasma (n = 204) and CSF (n = 147) EPO levels at admission were measured by radioimmunoassay and compared with mortality and neurologic outcomes. RESULTS: After adjustment for age and hemoglobin level, a 1-natural-log increase in plasma EPO level was associated with a 1.74-fold increase in mortality (95% confidence interval, 1.09-2.77, P = .02). Plasma and CSF EPO levels also correlated positively with coma duration (P = .05 and P = .02, respectively). Plasma and CSF EPO levels did not differ in children with vs those without acute or long-term neurologic deficits. Plasma EPO levels correlated positively with markers of endothelial and platelet activation and histidine-rich protein-2 levels, but remained associated with mortality after adjustment for these factors. CONCLUSIONS: High endogenous plasma EPO levels are associated with prolonged coma duration and increased mortality in children >18 months of age with CM.
Authors: P J Stohlawetz; L Dzirlo; N Hergovich; E Lackner; C Mensik; H G Eichler; E Kabrna; K Geissler; B Jilma Journal: Blood Date: 2000-05-01 Impact factor: 22.113
Authors: A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi Journal: Proc Natl Acad Sci U S A Date: 2001-03-20 Impact factor: 11.205
Authors: H H Marti; R H Wenger; L A Rivas; U Straumann; M Digicaylioglu; V Henn; Y Yonekawa; C Bauer; M Gassmann Journal: Eur J Neurosci Date: 1996-04 Impact factor: 3.386
Authors: Robin K Ohls; Beena D Kamath-Rayne; Robert D Christensen; Susan E Wiedmeier; Adam Rosenberg; Janell Fuller; Conra Backstrom Lacy; Mahshid Roohi; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Hannah Peceny; Daniel C Cannon; Jean R Lowe Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Chandy C John; Paul Bangirana; Justus Byarugaba; Robert O Opoka; Richard Idro; Anne M Jurek; Baolin Wu; Michael J Boivin Journal: Pediatrics Date: 2008-06-09 Impact factor: 7.124
Authors: Isabelle M Medana; Nicholas P J Day; Tran Tinh Hien; Nicholas J White; Gareth D H Turner Journal: Malar J Date: 2009-11-22 Impact factor: 2.979
Authors: Natalia Tiberti; Sharissa L Latham; Stephen Bush; Amy Cohen; Robert O Opoka; Chandy C John; Annette Juillard; Georges E Grau; Valéry Combes Journal: Sci Rep Date: 2016-12-05 Impact factor: 4.379
Authors: Dibyadyuti Datta; Paul Bangirana; Robert O Opoka; Andrea L Conroy; Katrina Co; Caitlin Bond; Yi Zhao; Keisuke Kawata; Andrew J Saykin; Chandy C John Journal: JAMA Netw Open Date: 2021-12-01
Authors: Estela Shabani; Robert O Opoka; Paul Bangirana; Gregory S Park; Gregory M Vercellotti; Weihua Guan; James S Hodges; Thomas Lavstsen; Chandy C John Journal: Sci Rep Date: 2016-06-03 Impact factor: 4.379